Bio-Techne Q4 Revenue Beats, Adjusted EPS Meets as Merck Deal Looms
TECH sits 67% above its 52-week low of $43.195.
Summary
Bio-Techne reported Q4 FY2026 revenue of $321.19M, up 3% year-over-year and beating the $314.68M consensus. Adjusted EPS of $0.52 met expectations, while GAAP EPS swung to a $0.35 profit from a loss last year. Margin improvement was driven by profitability initiatives and the divestiture of Exosome Diagnostics, partially offset by unfavorable product mix. The company did not provide forward guidance, consistent with its pending acquisition by Merck KGaA for $73 per share. With the stock trading near $72.20, just below the deal price, these results reinforce the fundamental value underpinning the transaction. The preliminary proxy was filed two days ago, and the shareholder vote timeline will be the next key catalyst.
At the time of this announcement, TECH was trading at $72.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $43.20 to $72.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.